Evasion of a single-step, chemotherapy-induced senescence in breast cancer cells: Implications for treatment response

Clinical Cancer Research

Volumn 11, Issue 7, 2005, Pages 2637-2643

  Elmore, Lynne W ^a   Di, Xu ^a   Dumur, Catherine ^a   Holt, Shawn E ^a   Gewirtz, David A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN P53; TELOMERASE;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CELL CLONE; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG RESISTANCE; ENZYME ACTIVITY; GAMMA IRRADIATION; GENE EXPRESSION PROFILING; GENE PROBE; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENESCENCE; TREATMENT OUTCOME; WESTERN BLOTTING;

ANTIBIOTICS, ANTINEOPLASTIC; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; BREAST NEOPLASMS; CAMPTOTHECIN; CELL AGING; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CLONE CELLS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GAMMA RAYS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; IMMEDIATE-EARLY PROTEINS; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-BCL-2; TELOMERASE; TENIPOSIDE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 17644368915     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1462     Document Type: Article

References (39)

1. Wright WE, Shay JW. The two-stage mechanism controlling cellular senescence and immortalization. Exp Gerontol 1992;27:383-9.
2. Vaziri H, Benchimol S. Reconstitution of telomerase in normal human cells leads to elongation of telomeres and extended replicative life span. Curr Biol 1998;8:279-82.
3. Kim NW, Piatyszek MA, Prowse KB, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-5.
4. te Poele RH, Okorokov AL, Jardine L, Cummings J, Joel SP. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res 2002;62:1876-83.
5. Schmitt CA, Fridman JS, Yang M, et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002;109:335-46.
6. Elmore LW, Rehder CW, Di X, et al. Adriamycin-induced senescence in breast tumor cells involves functional p53 and telomere dysfunction. J Biol Chem 2002;277:35509-15.
7. Wang Y, Zhu S, Cloughesy TF, Liau LM, Mischel PS. P53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition. Oncogene 2004;23:1283-90.
8. Chang BD, Swift ME, Shen M, Fang J, Broude EV, Roninson IB. Molecular determinants of terminal growth arrest induced in tumors by chemotherapeutic agent. Proc Natl Acad Sci U S A 2002;99:389-94.
9. Shay JW, Roninson IB. Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 2004;23:2929-33.
10. Gamel JW, Bonadonna G, Valagussa P, Edwards MJ. Refined measurement of outcome for adjuvant breast carcinoma therapy Cancer 2003;97:1139-46.
11. Gianni L, Valagussa P, Zambetti M, Moliterni A, Capri G, Bobadonna G. Adjuvant and neoadjuvant treatment of breast cancer. Semin Oncol 2001;28:13-29.
12. Dimri GP, Lee X, Basile G, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 1995;92:9362-7.
13. Liu WM, Mei R, Bartell DM, Di X, Webster TA, Ryder T. Rank-based Algorithms for Analysis of Microarrays. Proc SPIE 2001;4266:56-67.
14. Ford JM, Prozialeck WC, Hait WN. Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Mol Pharmacol 1989; 35:105-15.
15. Elmore LW, Turner KC, Gollahon LS, Landon MR, Jackson-Cook CK, Holt SE. Telomerase protects cancer-prone human cells from chromosomal instability and spontaneous immortalization. Cancer Biol Ther 2002;1:391-7.
16. Chang BD, Xuan Y, Broude EV, et al. Role of p53 and p21 waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene 1999;26:18:4808-18.
17. Brooks CL, Gu W. Ubiquitinization, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol 2003;15:164-71.
18. Vickers PJ, Dickson RB, Shoemaker R, Cowan KH. A multidrug resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to anti-estrogens and hormone independent tumor growth. Mol Endocrinol 1988;2:886-92.
19. Zyad A, Bernard J, Clarke R, Tursz T, Brockhaus M, Choualb S. Human breast cancer cross resistance to TNF and adriamycin: relationship to MDR1, MnSOD, and TRF gene expression. Cancer Res 1994;54:825-31.
20. Ramachandran C, Wellham LL. Effect of MDR1 phosphrothioate antisense oligodeoxynucleotides in multidrug-resistant human tumor cell lines and xenographs. Anticancer Res 2003;23:2681-91.
21. Cortes U, Moyret-Lalle C, Falette N, et al. BTG gene expression in the p53-dependent and -independent cellular response to DNA damage. Mol Carcinog 2000;27:57-64.
22. Charles AG, Han TY, Liu YY, Hansen N, Giuliano AE, Cabot MC. Taxol-induced ceramide generation and apoptosis in human breast cancer cells. Cancer Chemo Pharmacol 2001;47:444-50.
23. Watson JD. Origin of concatameric T4 DNA. Nat New Biol 1972;239:197-201.
24. Olovnikoff AM. Principle of marginotomy in template synthesis of oligonucleotides. Dokl Biochem 1971;201:394-7.
25. Yu G-L, Blackburn EH. Developmentally programmed healing of chromosomes by telomerase in Tetrahymena. Cell 1991;67:823-32.
26. Harrington LA, Greider CW. Telomerase primer specificity and chromosome healing. Nature 1991;353:451-4.
27. Masutomi K, Yu EY, Khurts S, et al. Telomerase maintains telomere structure in normal human cells. Cell 2003;114:241-53.
28. Bunn PA. Chemotherapy for the advanced small-cell-lung-cancer: who, what, when, and why? J Clin Oncol 2002;20:23-33S.
29. Van Cutsem E, Haller D, Ohtsu A. The role of chemotherapy in the current treatment of gastric cancer. Gastric Cancer 2002;5:17-22.
30. Kudoh K, Ramanna M, Ravatn R, et al. Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res 2000;60:4161-6.
31. Hutchison F. Chemical changes induced in DNA by ionizing radiation. Prog Nucleic Acid Res Mol Biol 1985;2:115-54.
32. Ward JF. DNA damage produced by ionizing radiation in mammalian cells: identities, mechanisms of formation and reparability. Prog Nucleic Acids Res Mol Biol 1988;5:95-125.
33. Prise KM, Pinto M, Newman HC, Michael BD. A review of studies of ionizing radiation-induced double strand break clustering. Radiat Res 2001;156:572-6.
34. Clarke R. Issues of experimental design and endpoint analysis in the study of experimental cytotoxic agents in vivo in breast cancer and other models. Breast Cancer Res Treat 1997;46:255-78.
35. Richter KH, Afshari CA, Annab LA, et al. Down-regulation of cdc2 in senescent human and hamster cells. Cancer Res 1991;51L6010-3.
36. Winter ZE, Ongkeko WM, Harris AL, Norbury CJ. P53 regulates cdc2 independently of inhibitory phosphorylation to reinforce radiation-induced sensitivity G2 arrest in human cells. Oncogene 1998;17:673-84.
37. 2-M arrest. Cancer Res 2000;60:542-5.
38. 2-M checkpoint regulators cyclin B1 and cdc2 in nonmalignant and malignant human breast lesions: immunocytochemical and quantitative image analysis. Am J Pathol 1997;150:15-23.
39. Jin YH, Park CK. Expression of cyclin B1 and cdc2 in nodal non-Hodgkin's lymphoma: relational to cell death, proliferation, and transformation. Cancer Res 2000;17:322-7.